Subsequently, a series of studies focused on detection of EGFR or KRAS mutations as TR-ctDNA in urine of patients with non-small cell lung cancer (Berz et al. 2015; Reckamp et al. 2016; Chen et al. 2017; Tchekmedyian et al. 2017; Husain et al. 2017; Franovic et al. 2017; F. Li et al. 2017; Wang et al. 2017; H. Zhang et al. 2018; Hu et al. 2018; Jin, Gou, and Qian 2019). This evidence concerns the gene KRAS and non-small cell lung carcinoma.